| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | VEGFR1 |
| Uniprot No | P17948 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 25-688aa |
| 氨基酸序列 | SGSKLKDPELSLKGTQHIMQAGQTLHLQCRGEAAHKWSLPEMVSKESERL SITKSACGRNGKQFCSTLTLNTAQANHTGFYSCKYLAVPTSKKKETESAI YIFISDTGRPFVEMYSEIPEIIHMTEGRELVIPCRVTSPNITVTLKKFPL DTLIPDGKRIIWDSRKGFIISNATYKEIGLLTCEATVNGHLYKTNYLTHR QTNTIIDVQISTPRPVKLLRGHTLVLNCTATTPLNTRVQMTWSYPDEKNK RASVRRRIDQSNSHANIFYSVLTIDKMQNKDKGLYTCRVRSGPSFKSVNT SVHIYDKAFITVKHRKQQVLETVAGKRSYRLSMKVKAFPSPEVVWLKDGL PATEKSARYLTRGYSLIIKDVTEEDAGNYTILLSIKQSNVFKNLTATLIV NVKPQIYEKAVSSFPDPALYPLGSRQILTCTAYGIPQPTIKWFWHPCNHN HSEARCDFCSNNEESFILDADSNMGNRIESITQRMAIIEGKNKMASTLVV ADSRISGIYICIASNKVGTVGRNISFYITDVPNGFHVNLEKMPTEGEDLK LSCTVNKFLYRDVTWILLRTVNNRTMHYSISKQKMAITKEHSITLNLTIM NVSLQDSGTYACRARNVYTGEEILQKKEITIRGEHCNKKAVFSRISKFKS TRNDCTTQSNVKH |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于VEGFR1重组蛋白的3篇代表性文献及其摘要概括：
1. **文献名称**：*Vascular endothelial growth factor receptor-1 (VEGFR1) regulates post-natal angiogenesis through interaction with VEGFR2*
**作者**：Ferrara N. et al.
**摘要**：研究利用重组VEGFR1蛋白揭示其通过负向调控VEGFR2信号通路抑制血管过度生成，阐明其在维持血管稳态中的作用。
2. **文献名称**：*Characterization of a soluble recombinant form of VEGFR1 (sFlt-1) and its anti-angiogenic activity*
**作者**：Shibuya M. et al.
**摘要**：报道重组sFlt-1蛋白的表达与纯化方法，证明其通过结合VEGF-A抑制内皮细胞增殖，为抗血管生成治疗提供实验基础。
3. **文献名称**：*VEGFR1-specific peptide fused to recombinant protein enhances tumor targeting and anti-metastatic therapy*
**作者**：Kerbel R.S. et al.
**摘要**：构建靶向VEGFR1的重组融合蛋白，证实其选择性抑制肿瘤血管生成并减少转移，推动靶向药物开发研究。
注：以上文献为示例性质，实际引用需核对具体来源。如需精准文献，建议通过PubMed或Web of Science检索关键词"VEGFR1 recombinant protein"。
Vascular Endothelial Growth Factor Receptor 1 (VEGFR1), also known as Flt-1 (Fms-like tyrosine kinase-1), is a transmembrane tyrosine kinase receptor that plays a critical role in regulating angiogenesis, vascular development, and pathological conditions like cancer and inflammatory diseases. It binds to ligands including VEGF-A, VEGF-B, and placental growth factor (PlGF), with distinct structural features: seven immunoglobulin-like domains in the extracellular region, a single transmembrane helix, and a split intracellular tyrosine kinase domain. Unlike VEGFR2. VEGFR1 exhibits weaker kinase activity and may act as a "decoy receptor" to modulate signaling dynamics by sequestering ligands.
Recombinant VEGFR1 proteins are typically produced in mammalian or insect expression systems to ensure proper post-translational modifications (e.g., glycosylation). These proteins often include the extracellular ligand-binding domain (soluble VEGFR1 or sFlt-1), which serves as a research tool to study VEGF pathway interactions or as a therapeutic agent to inhibit excessive angiogenesis. For example, recombinant VEGFR1-Fc fusion proteins (e.g., aflibercept) are clinically used to block VEGF signaling in age-related macular degeneration and metastatic colorectal cancer.
In research, recombinant VEGFR1 enables mechanistic studies of ligand-receptor specificity, receptor dimerization, and downstream signaling crosstalk. Its soluble form is also explored as a biomarker for preeclampsia due to elevated sFlt-1 levels in maternal blood. Structurally, crystallography studies using recombinant VEGFR1 fragments have revealed binding interfaces critical for designing small-molecule inhibitors. Additionally, it serves as a negative regulator in vascular biology models, helping dissect compensatory mechanisms between VEGFR1 and VEGFR2.
×
